The patient-reported outcomes for the new brand-generic teriflunomide in relapsing-remitting multiple sclerosis.
Clin Neurol Neurosurg
; 246: 108552, 2024 Sep 11.
Article
en En
| MEDLINE
| ID: mdl-39270462
ABSTRACT
BACKGROUND:
Patient-reported outcomes (PROs) provide valuable insights into the impact of disease-modifying therapies (DMTs) on patients' daily lives and disease progression. This study evaluates treatment satisfaction and tolerability among patients using a brand-generic Teriflunomide (Tebazio®, 14â¯mg tablet) manufactured by Zistdaru Danesh Biopharmaceuticals. MATERIALS ANDMETHODS:
A Phase IV observational study was conducted on patients with Relapsing-Remitting Multiple Sclerosis (RRMS) who were either initiated on or switched to Teriflunomide 14â¯mg. The primary focus was on the medication's safety. Patient satisfaction was measured using the Treatment Satisfaction Questionnaire for Medication [Version 1.4] (TSQM-14). Additionally, medication adherence and discontinuation rates were monitored.RESULTS:
Of the 235 RRMS patients enrolled, participated in this study, all received the Teriflunomide treatment orally on a daily basis. Over the 18-month follow-up period, 25.96â¯% of patients discontinued the treatment. Discontinuation was mainly due to adverse events (11â¯%), lack of patient willingness to continue (12.7â¯%), and disease progression (4.2â¯%). The most commonly reported adverse events included dermatologic disorders, elevated liver enzymes, and gastrointestinal issues. TSQM-14 scores demonstrated significant improvements over the 18-month period. A high medication adherence rate of 98.1â¯% was also recorded.CONCLUSION:
Patients reported notable satisfaction with Teriflunomide, as reflected in their TSQM scores, which suggests a likelihood of improved patient adherence. The 14â¯mg brand-generic Teriflunomide was well-accepted by Iranian RRMS patients, with no significant concerns arising during the study. These findings also highlight the significance of patient-reported outcomes in DMTs, with potential benefits for adherence and clinical practice.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Clin Neurol Neurosurg
Año:
2024
Tipo del documento:
Article